Michael Davidson to Risk Assessment
This is a "connection" page, showing publications Michael Davidson has written about Risk Assessment.
Connection Strength
1.433
-
The incremental value of lipids and inflammatory biomarkers in determining residual cardiovascular risk. Curr Atheroscler Rep. 2011 Oct; 13(5):373-80.
Score: 0.206
-
How Genomics Is Personalizing the Management of Dyslipidemia and Cardiovascular Disease Prevention. Curr Cardiol Rep. 2018 10 17; 20(12):138.
Score: 0.084
-
Cardiorenal Safety of OTC Analgesics. J Cardiovasc Pharmacol Ther. 2018 03; 23(2):103-118.
Score: 0.080
-
Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol. 2013 Dec 10; 62(23):2178-84.
Score: 0.059
-
Clinical utility of inflammatory markers and advanced lipoprotein testing: advice from an expert panel of lipid specialists. J Clin Lipidol. 2011 Sep-Oct; 5(5):338-67.
Score: 0.051
-
The role of cardiologists in the management of patients with diabetes is evolving owing to the close relationship between diabetes and CAD. Introduction. Am J Cardiol. 2011 Aug 02; 108(3 Suppl):1B-2B.
Score: 0.051
-
Pharmacotherapy: Implications of high-dose statin link with incident diabetes. Nat Rev Cardiol. 2011 Aug 02; 8(10):543-4.
Score: 0.051
-
Pioglitazone versus glimepiride on coronary artery calcium progression in patients with type 2 diabetes mellitus: a secondary end point of the CHICAGO study. Arterioscler Thromb Vasc Biol. 2010 Sep; 30(9):1873-6.
Score: 0.047
-
Low high-density lipoprotein cholesterol and increased cardiovascular disease risk: an analysis of statin clinical trials. Am J Cardiol. 2009 Nov 16; 104(10 Suppl):3E-9E.
Score: 0.045
-
An urgent matter-identifying your patients' cardiovascular risk and improving their outcomes. Assessing cardiovascular risk one patient at a time. J Fam Pract. 2009 Nov; 58(11 Suppl Urgent):S26-31.
Score: 0.045
-
Apolipoprotein measurements: is more widespread use clinically indicated? Clin Cardiol. 2009 Sep; 32(9):482-6.
Score: 0.045
-
Updating the assessment of cardiac risk: beyond Framingham. Rev Cardiovasc Med. 2009; 10(2):63-71.
Score: 0.043
-
A review of the current status of the management of mixed dyslipidemia associated with diabetes mellitus and metabolic syndrome. Am J Cardiol. 2008 Dec 22; 102(12A):19L-27L.
Score: 0.043
-
Is LDL-C passed its prime? The emerging role of non-HDL, LDL-P, and ApoB in CHD risk assessment. Arterioscler Thromb Vasc Biol. 2008 Sep; 28(9):1582-3.
Score: 0.042
-
Review of the evidence for the clinical utility of lipoprotein-associated phospholipase A2 as a cardiovascular risk marker. Am J Cardiol. 2008 Jun 16; 101(12A):41F-50F.
Score: 0.041
-
Consensus panel recommendation for incorporating lipoprotein-associated phospholipase A2 testing into cardiovascular disease risk assessment guidelines. Am J Cardiol. 2008 Jun 16; 101(12A):51F-57F.
Score: 0.041
-
Prescription omega-3 fatty acids and their lipid effects: physiologic mechanisms of action and clinical implications. Expert Rev Cardiovasc Ther. 2008 Mar; 6(3):391-409.
Score: 0.040
-
Titration patterns with rosuvastatin as compared with other statins in clinical practice: a retrospective observational cohort study using an electronic medical record database. Clin Ther. 2007 Nov; 29(11):2385-94.
Score: 0.039
-
Plasminogen activator inhibitor-1 and the risk of Type 2 diabetes mellitus in American Indians: the Strong Heart Study. Diabet Med. 2006 Oct; 23(10):1158-9.
Score: 0.036
-
Application of recent definitions of the metabolic syndrome to survey data from the National Cholesterol Education Program Evaluation Project Utilizing Novel E-Technology (NEPTUNE II). J Cardiometab Syndr. 2006; 1(5):295-300.
Score: 0.035
-
Reducing cardiovascular risk: trends in risk, risk assessment, and cholesterol management. Postgrad Med. 2004 Sep; 116(3 Suppl):7-12.
Score: 0.032
-
Emerging therapeutic strategies for the management of dyslipidemia in patients with the metabolic syndrome. Am J Cardiol. 2004 Jun 03; 93(11A):3C-11C.
Score: 0.031
-
Usefulness of Carotid Ultrasound Screening in Primary Cardiovascular Prevention: A Systematic Review. Curr Probl Cardiol. 2024 Jan; 49(1 Pt C):102147.
Score: 0.030
-
Cholesterol-lowering drugs bring benefits to high-risk populations even when LDL is normal. J Cardiovasc Nurs. 2003 Jan-Mar; 18(1):44-9; quiz 75-6.
Score: 0.028
-
Strategies to improve Adult Treatment Panel III guideline adherence and patient compliance. Am J Cardiol. 2002 Mar 07; 89(5A):8C-20C; discussion 20C-22C.
Score: 0.027
-
Associations between lower levels of low-density lipoprotein cholesterol and cardiovascular events in very high-risk patients: Pooled analysis of nine ODYSSEY trials of alirocumab versus control. Atherosclerosis. 2019 09; 288:85-93.
Score: 0.022
-
Lipoprotein(a) reductions from PCSK9 inhibition and major adverse cardiovascular events: Pooled analysis of alirocumab phase 3 trials. Atherosclerosis. 2019 09; 288:194-202.
Score: 0.022
-
Exposure to Antidepressant Medication and the Risk of Incident Dementia. Am J Geriatr Psychiatry. 2019 11; 27(11):1177-1188.
Score: 0.022
-
Large high-density lipoprotein particle number is independently associated with microvascular function in patients with well-controlled low-density lipoprotein concentration: A vasodilator stress magnetic resonance perfusion study. J Clin Lipidol. 2016 Mar-Apr; 10(2):314-22.
Score: 0.017
-
Efficacy and safety of dalcetrapib in type 2 diabetes mellitus and/or metabolic syndrome patients, at high cardiovascular disease risk. Diabetes Obes Metab. 2012 Jan; 14(1):30-9.
Score: 0.013
-
Baseline lipoprotein lipids and low-density lipoprotein cholesterol response to prescription omega-3 acid ethyl ester added to Simvastatin therapy. Am J Cardiol. 2010 May 15; 105(10):1409-12.
Score: 0.012
-
The editor's roundtable: the JUPITER trial--initial results and clinical implications. Am J Cardiol. 2009 May 15; 103(10):1417-25.
Score: 0.011
-
The use of high-sensitivity assays for C-reactive protein in clinical practice. Nat Clin Pract Cardiovasc Med. 2008 Oct; 5(10):621-35.
Score: 0.010
-
Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation. J Am Coll Cardiol. 2008 Apr 15; 51(15):1512-24.
Score: 0.010
-
Impaired diurnal blood pressure variation and all-cause mortality. Am J Hypertens. 2008 Jan; 21(1):92-7.
Score: 0.010
-
Economic cost of Alzheimer disease in Israel. Alzheimer Dis Assoc Disord. 2002 Apr-Jun; 16(2):73-80.
Score: 0.007
-
Assessing cardiovascular risks versus clinical benefits of atypical antipsychotic drug treatment. J Clin Psychiatry. 2002; 63 Suppl 9:25-9.
Score: 0.007